Analysis of innate immune cell populations showed that VVL-TD-mIL-27 treatment increased the proportion of CD86+ DC cells at day 6 (figure 7F), and VVL-TD-mIL-27 treatment decreased NK cells compared with PBS treatment at day 6, and a phenomenon also observed in the VVL-TD-RFP-treated group at day 12 (figure 7G), which is in contrast to the results observed in tumor tissues, likely due to the mobilization to the TME. Here, CD86 is linked to neoplasm.